Showing results (191-200 of 233) with videos related to

Sort By:
Pageof 24
Targeted Oncology|May 10, 2021
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line TreatmentPina Ziranu, Eleonora Lai, Marta Schirripa, et al.
International Journal of Cancer|June 9, 2022
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trialAlessandra Raimondi, Giovanni Randon, Michele Prisciandaro, et al.
Cancers|May 28, 2020
From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR TherapyRiccardo Giampieri, Pina Ziranu, Bruno Daniele, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studiesCarlotta Antoniotti, Marco M Germani, Daniele Rossini, et al.
Oncotarget|March 1, 2018
<i>DPYD</i> and <i>UGT1A1</i> genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancerChiara Cremolini, Marzia Del Re, Carlotta Antoniotti, et al.
Clinical Colorectal Cancer|March 19, 2023
Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA TrialDebora Basile, Gerardo Rosati, Francesca Bergamo, et al.
The Oncologist|September 8, 2018
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN StudyEric Van Cutsem, Erika Martinelli, Stefano Cascinu, et al.
Cancer Medicine|June 6, 2023
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinomaLetizia Procaccio, Valeria Merz, Morena Fasano, et al.
Cancers|February 25, 2022
Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal AntibodiesAnna Maria Rachiglio, Laura Forgione, Raffaella Pasquale, et al.
British Journal of Cancer|May 20, 2020
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trialsGiovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti, et al.
Pageof 24